Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seviteronel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 13/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seviteronel SCHEMBL29364397 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL23299702 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL30596789 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL4561168 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5020315 | 0.89 | CYP3A4 (0.68) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5020196 | 0.88 | CYP3A4 (0.65) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL8745699 | 0.85 | CYP3A4 (0.49) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4560966 | 0.82 | CYP3A4 (0.47) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL29892874 | 0.81 | CYP3A4 (1.00) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL29892604 | 0.81 | CYP3A4 (1.00) | CYP3A4CYP17A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131007-A1 | METHODS AND COMPOSITIONS FOR PICORNAVIRUS ANTI-VIRAL AGENTS | UNIVERSITY OF CONNECTICUT | 2024-04-25 | — | — | US | disclosed |
| EP-3527210-B1 | COMBINED COMPOSITION COMPRISING A BENZOHETEROCYCLIC COMPOUND AND AN ANDROGEN RECEPTOR PATHWAY MODULATOR AND USES THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20210113545-A1 | Pharmaceutical Composition Comprising a Benzoheterocyclic Compound and Androgen Receptor Pathway Modulator and Application Thereof | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-04-22 | — | — | US | disclosed |
| US-10933059-B2 | Combination, application thereof and treatment method | KANGPU BIOPHARMACEUTICALS. LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| EP-3527210-A1 | COMPOSITION, APPLICATION THEREOF AND TREATMENT METHOD | Kangpu Biopharmaceuticals, Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-3357513-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328722-A1 | COMBINATION, APPLICATION THEREOF AND TREATMENT METHOD | CYP21A2, CYP17A1, NR5A1 | CYP17A1 2/4885CYP3A4 236/4885CYP2C9 314/4885 |
| US-20210113545-A1 | Pharmaceutical Composition Comprising a Benzoheterocyclic Compound and Androgen Receptor Pathway Modulator and Application Thereof | AR, NR5A1, CYP17A1 | CYP17A1 3/4885CYP3A4 222/4885CYP2C9 112/4885 |
| US-10933059-B2 | Combination, application thereof and treatment method | CYP21A2, CYP17A1, NR5A1 | CYP17A1 2/4885CYP3A4 236/4885CYP2C9 314/4885 |
| US-20240131007-A1 | METHODS AND COMPOSITIONS FOR PICORNAVIRUS ANTI-VIRAL AGENTS | RNASEH1, HNRNPA2B1, HNRNPA1 | CYP17A1 2355/4885CYP3A4 4658/4885CYP2C9 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.